MacroGenics (MGNX) director Jay Siegel to step down after 2026 meeting

Rhea-AI Filing Summary

MacroGenics, Inc. reported that board member Jay Siegel, M.D. has informed the board that he will not stand for re-election as a Class I director at the company’s 2026 Annual Meeting of Stockholders. The company states that his decision is for personal reasons and not due to any disagreement regarding its operations, policies, or practices. MacroGenics thanks Dr. Siegel for his contributions to the company.

0001125345FALSE00011253452026-03-022026-03-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  March 2, 2026

MACROGENICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-36112

06-1591613

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer  Identification No.)

9704 Medical Center Drive

Rockville,

Maryland

20850

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:  (301) 251-5172

Not applicable 

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.01 per share			MGNX			Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 25, 2026, Jay Siegel, M.D. informed the board of directors (the “Board”) of MacroGenics, Inc. (the “Company”) that he will not stand for re-election as a Class I director at the Company’s 2026 Annual Meeting of Stockholders. Dr. Siegel’s decision was for personal reasons and was not the result of any disagreement with the Company or any matter relating to the Company’s operations, policies or practices. The Company thanks Dr. Siegel for his many contributions to the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 2, 2026

MACROGENICS, INC.

By: /s/ Jeffrey Peters       Jeffrey Peters       Senior Vice President, General Counsel and Corporate Secretary

FAQ

What board change did MacroGenics (MGNX) disclose in this 8-K?

MacroGenics disclosed that director Jay Siegel, M.D. will not stand for re-election as a Class I director at the company’s 2026 Annual Meeting of Stockholders, citing personal reasons and no disagreements with the company’s operations or policies.

Did Jay Siegel, M.D. resign from the MacroGenics (MGNX) board immediately?

No, Jay Siegel, M.D. did not resign immediately. He informed MacroGenics’ board that he will not stand for re-election as a Class I director at the 2026 Annual Meeting, meaning he is expected to serve until his current term ends.

Did MacroGenics (MGNX) report any disagreement related to Jay Siegel’s decision?

MacroGenics stated that Dr. Siegel’s decision not to stand for re-election was for personal reasons and not the result of any disagreement with the company or with its operations, policies, or practices, indicating no reported conflict behind the decision.

What type of SEC filing did MacroGenics (MGNX) use for this board update?

MacroGenics used a Form 8-K to report the planned departure of director Jay Siegel, M.D. at the end of his current term, as he will not stand for re-election at the 2026 Annual Meeting of Stockholders.

How did MacroGenics (MGNX) characterize Jay Siegel’s service on its board?

MacroGenics expressed appreciation for Dr. Siegel, noting that the company thanks him for his many contributions. This language signals recognition of his role and service as a Class I director on the board.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB